Internal Medicine, Hematology & Oncology · Winston Salem, NC
NPI
1659551604
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
Medical Center Blvd
Winston Salem, NC, 27157
Phone (336) 716-2255
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.9M
121,435 services
Medicare patients, 2024
469
Average age 74
Drug cost, 2024
$5.6M
2,583 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jing Li was code J1439 (injection, ferric carboxymaltose, 1 mg), 40,500 times for 24 patients. In total Jing Li billed 121,435 services in 111 codes, and Medicare paid $1.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-03-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 40,500 | 24 | $0.87 | $35K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 9,900 | 12 | $0.11 | $1,119 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,497 | 18 | $0.07 | $108 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,370 | 21 | $0.09 | $121 |
| 85025 Blood Count | Office | 1,079 | 378 | $7.60 | $8,204 |
| 99214 Office E&M - Established | Office | 802 | 319 | $87.44 | $70K |
| Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 492 | 14 | $115.19 | $57K |
| 80053 Clinical Chemistry | Office | 325 | 56 | $10.35 | $3,364 |
| 96375 Injection Administration | Office | 320 | 32 | $11.07 | $3,542 |
| 96413 Chemotherapy Administration | Office | 276 | 41 | $90.47 | $25K |
| 96372 Injection Administration | Office | 242 | 48 | $9.97 | $2,414 |
| 99213 Office E&M - Established | Office | 229 | 161 | $60.48 | $14K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 181 | 11 | $4.73 | $856 |
| 96367 Intravenous Infusion, Hydration | Office | 106 | 15 | $20.37 | $2,159 |
| 96417 Chemotherapy Administration | Office | 96 | 17 | $45.66 | $4,383 |
By year: 2022 $1.2M for 77,190 services; 2023 $1.2M for 52,353 services; 2024 $1.9M for 121,435 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,079 | 378 | $7.60 | $8,204 |
| 80053 Clinical Chemistry | 325 | 56 | $10.35 | $3,364 |
| 36415 Venipuncture Blood Collection | 16 | 15 | $8.11 | $130 |
| 82270 Immunoassay | 11 | 11 | $4.29 | $47.19 |
Medicare prescription drug claims, 2024
In 2024, the drug Jing Li prescribed most often to Medicare patients was Letrozole, with 283 prescriptions and refills. In total Jing Li wrote 2,583 Medicare prescriptions that cost $5.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 283 | 536 | 59 | $4,554 |
| Eliquis Apixaban | 189 | 268 | 42 | $150K |
| Ondansetron Hcl Generic | 143 | 144 | 73 | $901 |
| Gabapentin Generic | 123 | 156 | 26 | $1,098 |
| Prochlorperazine Maleate Generic | 114 | 114 | 52 | $1,298 |
| Alendronate Sodium Generic | 113 | 180 | 23 | $773 |
| Prednisone Generic | 113 | 133 | 31 | $474 |
| Hydroxyurea Generic | 86 | 140 | 16 | $1,868 |
| Abiraterone Acetate Generic | 82 | 82 | 12 | $175K |
| Anastrozole Generic | 68 | 186 | 20 | $1,230 |
| Xtandi Enzalutamide | 66 | 66 | 11 | $914K |
| Dexamethasone Generic | 65 | 67 | 27 | $1,298 |
| Xarelto Rivaroxaban | 58 | 89 | Under 11 | $49K |
| Tamoxifen Citrate Generic | 50 | 112 | 13 | $1,026 |
| Revlimid Lenalidomide | 44 | 44 | Under 11 | $764K |
Brand drugs: 588 claims; generic drugs: 1,995 claims; opioid claims: 113.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Jing Li were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.